Amani Bouabdallah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amani Bouabdallah has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Haifa Sanhaji
Faculty of Medicine of Tunis, University of Tunis El Manar, Jebbari, Tunis 1007, Tunisia
1 shared publication - Mohamed Bessem Hammami
LR99ES11, Faculty of Medicine of Tunis, Rabta Hospital, University of Tunis El Manar, Tunis 1007, Tunisia
1 shared publication - Mohamed Kacem Ben-Fradj
Faculty of Medicine of Tunis, University of Tunis El Manar, Jebbari, Tunis 1007, Tunisia
1 shared publication - Moncef Feki
Faculty of Medicine of Tunis University of Tunis el Manar Rabta Hospital Tunis Tunisia
1 shared publication - Rim Abdelmalek
Faculty of Medicine of Tunis, University of Tunis El Manar, Jebbari, Tunis 1007, Tunisia
1 shared publication - Timothée Klopfenstein
Infectious Diseases and Tropical Medicine Department, Nord-Franche-Comté Hospital, 90400 Trevenans, France
1 shared publication
Latest Publications
- Open Access
- 19 November 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (11) , 2622
COVID-19 is Associated with a Lipid Storm that Worsens in Cases of Severe Pneumonia
Severe Coronavirus disease 2019 (COVID-19) is associated with abnormal innate and adaptive immune responses, as well as systemic alterations, including a shift in lipid network. A case–control study was conducted to describe the systemic lipidomic profile in COVID-19 according to disease severity. Selected polyunsaturated fatty acids (PUFAs), oxylipins, and endocannabinoids were analysed using a targeted liquid chromatography coupled to mass spectrometry in tandem method. Multivariate receiver operating characteristic curve-based model evaluation was performed to define a lipidomic signature for the disease. A total of 135 hospitalized COVID-19 patients, of whom 85 had severe form, and 134 healthy individuals were included. Patients exhibited increased levels of free PUFAs, proinflammatory and pro-resolving oxylipins, and endocannabinoids compared to controls. A combination of five lipid mediators, i.e., prostaglandin D2, prostaglandin E2, thromboxane B2, lipoxin B4, and 2-archidonylglycerol, discriminates patients from control individuals with excellent accuracy [AUC, 0.977 (0.950–0.995)]. The severe form is characterized by an imbalance between proinflammatory and pro-resolving oxylipins and increased endocannabinoids. COVID-19 is associated with a lipid storm that conditions disease severity. Targeting lipid mediators-related metabolic and signalling pathways could be an interesting therapeutic option in severe forms.
- 19 November 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (11) , 2622
Open AccessCOVID-19 is Associated with a Lipid Storm that Worsens in Cases of Severe Pneumonia
Severe Coronavirus disease 2019 (COVID-19) is associated with abnormal innate and adaptive immune responses, as well as systemic alterations, including a shift in lipid network. A case–control study was conducted to describe the systemic lipidomic profile in COVID-19 according to disease severity. Selected polyunsaturated fatty acids (PUFAs), oxylipins, and endocannabinoids were analysed using a targeted liquid chromatography coupled to mass spectrometry in tandem method. Multivariate receiver operating characteristic curve-based model evaluation was performed to define a lipidomic signature for the disease. A total of 135 hospitalized COVID-19 patients, of whom 85 had severe form, and 134 healthy individuals were included. Patients exhibited increased levels of free PUFAs, proinflammatory and pro-resolving oxylipins, and endocannabinoids compared to controls. A combination of five lipid mediators, i.e., prostaglandin D2, prostaglandin E2, thromboxane B2, lipoxin B4, and 2-archidonylglycerol, discriminates patients from control individuals with excellent accuracy [AUC, 0.977 (0.950–0.995)]. The severe form is characterized by an imbalance between proinflammatory and pro-resolving oxylipins and increased endocannabinoids. COVID-19 is associated with a lipid storm that conditions disease severity. Targeting lipid mediators-related metabolic and signalling pathways could be an interesting therapeutic option in severe forms.